688331:SSERemeGen Co. Ltd. Class A Analysis

RemeGen trades around 114 CNY, which is nearly double the DCF‑derived fair value of 60 CNY, and its trailing PE of 88x dwarfs the biotechnology industry average of 24x. The company is posting robust top‑line momentum, with revenue up 24.8% year‑over‑year and an eye‑popping gross margin of 86.9%, yet operating profitability remains negative at -3.4% and the profit margin is buoyed by non‑operating items. A solid cash pile of 2.74 bn CNY comfortably exceeds its debt of 2.09 bn CNY, delivering a net‑cash position, while an impressive ROE of 45% signals efficient capital use.
On the technical side, price sits above the 20‑day SMA (109) but below the 50‑day SMA (122), the MACD histogram is positive and the signal line is bullish, suggesting short‑term upside potential, yet trading volume is on a downtrend and 30‑day volatility is high at 54.8%. The stock’s beta near 1.0 indicates market‑level systematic risk, and the biotech sector carries inherent regulatory and clinical‑trial uncertainties.
Given the lack of dividend, extreme overvaluation, and high valuation multiples, the investment thesis leans on the company’s pipeline of ADCs and high‑margin products. However, the combination of operating losses, regulatory risk, and a price already far above intrinsic estimates tempers enthusiasm, making a cautious stance prudent across horizons.